Molecular mechanisms of aberrant neutrophil differentiation in glycogen storage disease type Ib

Sang Wan Sim

Korea University - Sejong Campus

Yuyeon Jang

Korea University - Sejong Campus

Tae Sub Park

Seoul National University

Byung-Chul Park

Seoul National University

Young Mok Lee

University of Connecticut Health Center: UConn Health

Hyun Sik Jun (✉ toddjun@korea.ac.kr)

Korea University - Sejong Campus <https://orcid.org/0000-0002-1570-7784>

Research Article

Keywords: myeloid progenitor cells, glucose-6-phosphate transporter, CRISPR/Cas9, peroxisome proliferator-activated receptor-γ

Posted Date: January 27th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1271259/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Cellular and Molecular Life Sciences on April 18th, 2022. See the published version at <https://doi.org/10.1007/s00018-022-04267-5>.

Abstract

Glycogen storage disease type Ib (GSD-Ib), characterized by impaired glucose homeostasis, neutropenia, and neutrophil dysfunction, is caused by a deficiency in glucose-6-phosphate transporter (G6PT). Neutropenia in GSD-Ib has been known to result from enhanced apoptosis of neutrophils. However, it has also been raised that neutrophil maturation arrest in the bone marrow would contribute to neutropenia. We now show that *G6pt*^{-/-} mice exhibit severe neutropenia and impaired neutrophil differentiation in the bone marrow. To investigate the role of G6PT in myeloid progenitor cells, the *G6PT* gene was mutated using CRISPR/Cas9 system, and single cell-derived *G6PT*^{-/-} human promyelocyte HL-60 cell lines were established. The *G6PT*^{-/-} HL-60s exhibited impaired neutrophil differentiation, which is associated with two mechanisms: i) abnormal lipid metabolism causing a delayed metabolic reprogramming and ii) reduced nuclear transcriptional activity of peroxisome proliferator-activated receptor-γ (PPARγ) in *G6PT*^{-/-} HL-60s. In this study, we demonstrated that G6PT is essential for neutrophil differentiation of myeloid progenitor cells and regulates PPARγ activity.

Introduction

Glycogen storage disease type Ib (GSD-Ib) is an autosomal-recessive syndrome characterized by impaired glucose homeostasis, neutropenia, and neutrophil dysfunction [1, 2]. GSD-Ib is caused by a mutation in the *SLC37A4* gene that results in disruption of the activity of glucose-6-phosphate (G6P) transporter (G6PT) [3]. G6PT transports G6P from the cytoplasm into the lumen of the endoplasmic reticulum (ER), where it is hydrolyzed into glucose and phosphate by glucose-6-phosphatase-α (G6Pase-α) or glucose-6-phosphatase-β (G6Pase-β) [1, 4]. GSD-Ib is characterized by hypoglycemia, accumulation of excessive glycogen, growth retardation, hyperlipidemia, neutropenia and myeloid dysfunctions [5, 6]. It has been shown that G6PT deficiency causes ER and mitochondrial oxidative stress-induced apoptosis that leads to neutropenia and impaired energy homeostasis, which underlies neutrophil dysfunction such as impaired respiratory burst, chemotaxis, and calcium mobilization activities [7]. In addition to apoptosis of neutrophils, several studies have shown that neutrophil maturation arrest in the bone marrow (BM) of some GSD-Ib patients might also contribute to neutropenia [8].

Granulocyte-colony stimulating factor (G-CSF) is widely used to increase absolute neutrophil counts and prevent bacterial infections in GSD-Ib patients. However, it has been reported that G-CSF therapy does not rescue the impairment in neutrophil migration and adhesion in *G6pt*^{-/-} mice [9]. Furthermore, long-term treatment with G-CSF might lead to acute myeloid leukemia or myelodysplastic syndromes, suggesting that G-CSF therapy is not sufficient for the treatment of neutropenia and neutrophil dysfunction [10]. Recently, it has been proposed that accumulation of 1,5-anhydroglucitol-6-phosphate (1,5-AG6P), a structural analog of G6P and newly discovered substrate for G6PT and G6Pase-β, strongly inhibits the activity of hexokinase in GSD-Ib patients, thereby blocking the first step of glycolysis [11]. This finding led to the observation that administration of a 1,5-AG6P-lowering drug, empagliflozin, treats neutrophil

dysfunction in GSD-Ib patients, but neutropenia was not cured in all patients [12]. Therefore, a molecular mechanism underlying neutrophil maturation arrest in GSD-Ib is further required.

Differentiation of neutrophils occurs in the BM and produces more than $1 \cdot 10^{11}$ neutrophils every day. In the process of neutrophil differentiation, myeloblasts are the first recognizable myeloid precursor cells. They terminally differentiate into mature neutrophils through morphologically different stages of promyelocytes, myelocytes, metamyelocytes, and band cells [13]. Neutrophils are known to mainly depend on glycolysis; however, several lines of evidence have identified the importance of fatty acid metabolism, the tricarboxylic acid cycle, and mitochondrial respiration during neutrophil development and maturation [14–16]. In particular, it has been observed that autophagy-mediated lipid droplet degradation generates free fatty acids that fuel oxidative phosphorylation (OXPHOS) and provide energy for metabolic reprogramming during neutrophil differentiation, especially in the early developmental stage of myeloblasts and myelocytes [14].

In this regard, we hypothesized that G6PT deficiency could alter the lipid metabolism of myeloid progenitor cells, consequently affecting neutrophil differentiation. We showed that *G6pt*^{-/-} mice exhibited neutropenia and neutrophil maturation arrest in the BM. To provide an insight into the function of G6PT in myeloid progenitor cells, we created G6PT-knockout human promyelocyte HL-60s using the CRISPR/Cas9 and tested their differentiation into neutrophils *in vitro*. We noted impaired neutrophil differentiation in *G6PT*^{-/-} HL-60s and found that this phenotype is associated with downregulation of nuclear peroxisome proliferator-activated receptor-γ (PPARγ) transcriptional activity and abnormal lipid metabolism. Therefore, we suggest that G6PT plays an essential role in neutrophil maturation through PPARγ regulation.

Materials And Methods

Animals

G6pt^{-/-} mice were infused with a recombinant adeno-associated virus serotype 8 (rAAV8) vector carrying human G6PT (hG6PT), because *G6pt*^{-/-} mice show a severely low survival rate without daily glucose therapy [17]. The AAV8-hG6PT-infused *G6pt*^{-/-} mice were maintained until sacrifice, and mice aged 5-12 weeks were used in these experiments.

Cell culture and neutrophil differentiation

The human promyelocytic cell line HL-60 was obtained from ATCC (American Type Culture Collection; ATCC-CCL-240). Cells were grown in RPMI-1640 (HyClone) supplemented with 10% heat-inactivated fetal bovine serum (Access Biologicals LLC) and 1% penicillin/streptomycin (HyClone) at 37°C in an atmosphere with 5% CO₂. The cultures were at densities between $1 \cdot 10^5$ and $1 \cdot 10^6$ viable cells/mL for constant exponential growth.

For neutrophil differentiation, the cells were cultured to $3 \cdot 10^5$ cells/mL with 1.25% dimethyl sulfoxide (DMSO) and 1 μ M all-trans retinoic acid (ATRA) treatment.

Flow cytometry analysis

Mouse peripheral blood and BM cells were treated with ammonium-chloride-potassium (ACK) lysis buffer (Thermo Scientific). The resulting leukocytes were stained with mouse phycoerythrin (PE)-conjugated granulocyte antigen-1 (Gr-1) antibody, mouse phycoerythrin-cyanine5.5 (PE-Cy5.5)-conjugated integrin alpha M (CD11b) antibody (eBioscience), mouse Alexa Fluor® 488-conjugated G-CSF receptor (G-CSFR) antibody (R&D Systems), and mouse Alexa Fluor® 405-conjugated C-X-C chemokine receptor type 4 (CXCR4) antibody (R&D Systems) for 20 min at 4°C in the dark. Cells were analyzed with an Attune NxT Flow Cytometer (Beckman Coulter).

Neutrophil differentiation of HL-60s was evaluated in terms of expression of CD71-PE, CD11b-fluorescein isothiocyanate (FITC, BioLegend), and CD38-PE-Cy5 (BD Biosciences). The cells were stained for 20 min at 4°C in the dark with antibodies, and flow cytometry was performed using a Guava® EasyCyte™ system (Millipore). The data were analyzed using FlowJo v7.0.

Isolation of murine BM neutrophils and their precursors

Using a mouse neutrophil isolation kit (Miltenyi Biotec), we isolated BM-derived neutrophils and their precursors from the femurs and tibias of mice at the age of 7-11 weeks. The procedure was performed as described previously [9]. In short, we removed erythrocytes from isolated BM cells using ACK lysing buffer (Thermo Scientific), and up to $1 \cdot 10^8$ cells were resuspended in PBS (pH 7.2) supplemented with 0.5% bovine serum albumin and 2 mM EDTA. To deplete non-neutrophil lineage cells, 50 μ L of Neutrophil Biotin-Antibody Cocktail (Miltenyi Biotec) was mixed with $5 \cdot 10^7$ cells and incubated at 4°C for 10 min. After washing with buffer, the samples were mixed with 100 μ L of Anti-Biotin Microbeads per $5 \cdot 10^7$ cells and incubated at 4°C for 15 min. Labeled neutrophils and neutrophil precursors were collected using a MACS® column (Miltenyi Biotec). The morphology of isolated cells was examined on Hema-3-stained (Thermo Scientific) cytopspin slides.

Immunofluorescence microscopy

To investigate the lipid droplets, differentiated HL-60s were plated onto glass slides using Cytospin™ 4 Cytocentrifuge (Thermo Scientific) and stained with 1 μ g/mL BODIPY 493/503 (Invitrogen, Carlsbad, CA, USA) and 4',6-diamidino-2-phenylindole (DAPI). The slides were imaged using an EVOS5000 system (Invitrogen).

To examine the localization of PPAR γ , cells were cytopspined and fixed in paraformaldehyde as described previously [7]. Cells were then permeabilized in 1.25% Triton™ X-100 and incubated with PPAR γ antibody (Santa Cruz Biotechnology) and appropriate immunoglobulin G antibody conjugated with Alexa Fluor® 594 (Invitrogen). Cells were visualized using a Zeiss LSM700 confocal microscope equipped with 40 $\times$ /1.3 numeric aperture oil objectives (Carl Zeiss Microimaging).

PPAR γ activity in vitro assay

PPAR γ activity was measured using a PPAR γ transcription factor assay kit (Abcam) and Nuclear Extraction Kit (Abcam), following the manufacturer's instructions. PPAR γ activity was measured at 450 nm using an absorbance microplate reader, Sunrise™ (Tecan), followed by incubation with PPAR γ primary antibody and secondary antibody conjugated to horseradish peroxidase.

Western blotting and quantitative real-time reverse transcription-polymerase chain reaction analysis

Western blot analysis was conducted as described previously [18]. The mouse monoclonal antibodies used were glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotechnology) and PPAR γ (Santa Cruz Biotechnology). The rabbit polyclonal antibodies used were full-length and cleaved poly (ADP-ribose) polymerase (PARP; Cell Signaling), PPAR γ (Santa Cruz Biotechnology), peroxisome proliferator-activated receptor- α (PPAR α , Santa Cruz Biotechnology), PU.1 (Santa Cruz Biotechnology), NAD-dependent protein deacetylase sirtuin 1 (SIRT1, Millipore), and total and phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2 and pERK1/2, respectively; Cell Signaling). Protein expression was quantified by means of densitometry analysis using ImageJ software v1.50 (National Institutes of Health).

Total RNA was extracted from HL-60s using the TRIzol® Reagent (Invitrogen). mRNA expression was quantified using real-time reverse transcription-polymerase chain reaction (RT-PCR) with an AriaMx Real-Time PCR System (Agilent Technologies) and normalized to 18S rRNA. The sequences of each primer pair are shown in Supplementary Table 1.

Real-time cell metabolism assay

The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined using the Seahorse XFp analyzer (Agilent Technologies), as described by Steven Messina-Graham et al [19].

Differentiated HL-60s (live $2.5 \cdot 10^5$) were plated using Cell-Tak™ (Corning). For measuring the OCR, 5 μ M oligomycin, 0.75 μ M carbonyl cyanide-*p*-trifluoromethoxyphenylhydrazone (FCCP), and 1.5 μ M Rotenone/Antimycin A were injected in the XFp Analyzer. To measure the ECAR, 10 mM glucose, 5 μ M oligomycin, and 50 μ M 2-Deoxy-D-glucose were added. Cellular respiration and glycolytic flux were quantified by the OCR (pmol/min) and ECAR (mpH/min), respectively.

Statistical analysis

Data have been represented as mean $\pm$ standard deviation and were assessed using Student's *t*-test with Prism 5 (GraphPad). Values were considered statistically significant at $P < 0.05$.

Results

G6pt^{-/-} mice exhibit neutropenia and abnormal expression of G-CSFR and CXCR4 in blood

G6pt^{-/-} mice suffer from frequent hypoglycemic seizures and a low survival rate without daily glucose therapy [20]. To increase their survival, *G6pt*^{-/-} mice received rAAV8-hG6PT as previously described [9]. The introduced G6PT transgene induces only transient expression of G6PT in the BM because the rAAV8-hG6PT vector primarily targeted the liver [17, 21]. Consequently, rAAV8-hG6PT could not correct the neutropenia in *G6pt*^{-/-} mice, and the levels of total neutrophils (CD11b⁺Gr-1⁺) in the erythrocyte-depleted blood leukocytes were analyzed using flow cytometry. *G6pt*^{-/-} mice exhibited severe neutropenia, with a significantly lower frequency of CD11b⁺Gr-1⁺ neutrophils (by 25.5%) in the peripheral blood, as compared to that in the control littermates (Fig. 1a). Neutropenia in the peripheral blood of *G6pt*^{-/-} mice was also confirmed by nuclear morphologic analysis of Hema-3-stained cytopsin slides (Fig. 1b).

GSD-1b patients showing neutropenia normally receive G-CSF therapy to increase their absolute neutrophil counts. The interesting thing is that they show increased plasma G-CSF levels even before receiving G-CSF therapy, however, the underlying cause why they do not respond to increased G-CSF is still not understood [20]. Also, it was reported that increased chemokine receptor CXCR4-mediated bone marrow retention mechanism might contribute to neutropenia [22]. In this point of view, we compared the expression of G-CSF receptor (G-CSFR) and chemokine receptor CXCR4 in CD11b⁺Gr-1⁺ neutrophils. As a result, there was a significant decrease in G-CSFR expression, while CXCR4 expression increased 5.8-fold in *G6pt*^{-/-} mice, as compared to that in control mice (Fig. 1c, d and Fig. S1a).

Impaired neutrophil differentiation in the BM of *G6pt*^{-/-} mice

G6pt^{-/-} mice showed significantly decreased neutrophil population in the BM compared with that in control mice (53.0% vs. 19.2% CD11b⁺Gr-1⁺ cells in the BM cells) (Fig. 2a). In this population, mature (CD11b⁺Gr-1⁺) neutrophils were also reduced to 36.3% in *G6pt*^{-/-} mice, as compared to that in control mice. Furthermore, immature myeloid precursor cells (CD11b⁻Gr-1⁺) accumulated 2.4-fold higher in *G6pt*^{-/-} mice than that in control mice, accounting for 50.5% of total Gr-1⁺ cells in the BM, while control mice had only 12.8%.

Expression of G-CSFR and CXCR4 in Gr-1⁺ neutrophil lineage cells was also examined in the BM of *G6pt*^{-/-} mice. G-CSFR expression was similar to that of control mice. However, the expression of CXCR4 increased by approximately 4.7-fold in *G6pt*^{-/-} mice compared with that in control mice (Fig. 2b, c and Fig. S1b). Accumulation of immature myeloid precursor cells in the BM of *G6pt*^{-/-} mice was confirmed by Hema-3-stained cytopsin slides (Fig. 2d). These results indicated that G6PT deficiency significantly inhibits the ability of myeloid progenitor cells to differentiate into neutrophils.

Decreased neutrophil differentiation of *G6PT*^{-/-} HL-60s

Since *G6pt*^{-/-} mice are rare, to further pursue mechanistic studies, we generated a *G6PT*^{-/-} clone via CRISPR/Cas9-mediated gene editing of the *in vitro* human promyelocyte line HL-60s (Fig. S2a-c). First, we examined cell growth by counting cells at the indicated time-points to investigate the proliferative activity

of *G6PT*^{-/-} HL-60s (Fig. 3a). *G6PT*^{-/-} HL-60s exhibited increased cell proliferation, as compared to control HL-60s in the absence of ATRA and DMSO. *G6PT*^{-/-} HL-60s also showed increased cell numbers up to 96 h after induction, while control HL-60s showed a decrease in cell number after 48 h, as neutrophil differentiation proceeded. Next, we examined the neutrophil differentiation of *G6PT*^{-/-} HL-60s to study the effect of G6PT deficiency. Neutrophil differentiation of HL-60s was analyzed by CD71 (undifferentiated HL-60 marker), CD38 (early differentiation marker), and CD11b (late differentiation marker) expression using flow cytometry and nuclear morphological analysis of Hema-3-stained cytospin slides [23]. The frequency of CD38⁺CD71⁻ cells and mean fluorescence intensity (MFI) of CD38 expression was significantly lower in *G6PT*^{-/-} HL-60s than in control HL-60s (Fig. 3b). The frequency of CD11b⁺CD71⁻ cells was also significantly lower in *G6PT*^{-/-} HL-60s, as compared to that in control HL-60s (Fig. 3c). Consistently, highly differentiated cells were not observed in *G6PT*^{-/-} HL-60s (Fig. 3d). These results indicated that G6PT deficiency results in maturation arrest from the early stages of neutrophil differentiation.

Interestingly, *G6PT*^{-/-} HL-60s showed a dramatic decrease in cell number 120 h after induction (Fig. 3a). Therefore, we assessed apoptosis of differentiated HL-60s using two apoptosis markers; externalization of phosphatidylserine on the plasma membrane and expression of cleaved PARP. As HL-60s differentiate into neutrophils, control HL-60s showed continuously increasing rates of apoptosis, while apoptosis rates of *G6PT*^{-/-} HL-60s were significantly low until 72 h and they increased after 96 h (Fig. 3e and S3a). On the other hand, cleaved PARP expression was upregulated in *G6PT*^{-/-} HL-60s from 72 h after induction (Fig. S3b), suggesting that cleaved PARP-mediated apoptosis would contribute to an increase of apoptosis in *G6PT*^{-/-} HL-60 from 96 h to 120 h (Fig. 3a).

GSD-1b patients suffer from hypoglycemia; therefore, the amount of glucose available for the myeloid progenitor cells in the BM of the patients would be lesser than the amount present in the culture condition (11 mM glucose). For this reason, we tested neutrophil differentiation of *G6PT*^{-/-} HL-60s depending on the glucose concentration in the media. While control HL-60s exhibited growth arrest from 48 h after induction in all conditions, *G6PT*^{-/-} HL-60s showed decreased proliferation depending on the glucose concentrations and did not show growth arrest (Fig. S4a, b). When we investigated neutrophil differentiation markers under these conditions, the MFI of CD38 expression and frequency of CD11b⁺ cells were significantly reduced in *G6PT*^{-/-} HL-60 cells, regardless of the glucose concentration (Fig. S4c). Impaired neutrophil maturation of *G6PT*^{-/-} HL-60s was also confirmed by assessing the Hema-3-stained cytospin slides (Fig. S4d). Along with these results, *G6PT*^{-/-} HL-60s exhibited glucose susceptibility compared to control HL-60s, when we treated 0.5 mM 2-deoxy-D-glucose (2-DG) that is a non-metabolizable glucose analog (Fig. S4e). Of note, inhibition of glycolysis by 2-DG slightly increased neutrophil differentiation in both control and *G6PT*^{-/-} HL-60s (Fig. S4f, g). These results suggested that glucose might affect the proliferation, but not maturation, during neutrophil differentiation of *G6PT*^{-/-} HL-60s.

Abnormal lipid metabolism and reduced nuclear PPAR γ activity of G6PT $^{-/-}$ HL-60s

Recently, the FAO and OXPHOS/mitochondrial respiration in neutrophil differentiation has been considered as a major metabolic pathway [24]. Therefore, we examined lipid droplets during neutrophil differentiation to investigate the molecular mechanisms governing impaired neutrophil differentiation in G6PT $^{-/-}$ HL-60s. There was a significant decrease in the amount of BODIPY-stained lipid droplets in undifferentiated G6PT $^{-/-}$ HL-60s, as compared to that in the control HL-60s (Fig. 4a). As differentiation proceeded, the size of lipid droplets became smaller and they almost disappeared at 48 h after induction in control HL-60s. However, G6PT $^{-/-}$ HL-60s showed very few lipid droplets and did not accumulate as much as those in control HL-60s for up to 96 h.

We then investigated the expression of PPAR γ and PPAR α , which regulate lipid metabolism and genes related to cell differentiation [25]. As shown in Fig. 4b, PPAR γ mRNA expression was downregulated in G6PT $^{-/-}$ HL-60s, while PPAR α mRNA expression was not significantly different in both control and G6PT $^{-/-}$ HL-60s during differentiation. On the other hand, western blot analysis showed that expression of PPAR α was upregulated in G6PT $^{-/-}$ HL-60s, whereas PPAR γ expression did not change during differentiation in both control and G6PT $^{-/-}$ HL-60s (Fig. 4c).

Even though PPAR γ protein expression in both control and G6PT $^{-/-}$ HL-60s was similar, PPAR γ mRNA expression was significantly lower in G6PT $^{-/-}$ HL-60s. In addition, PPAR γ is known to induce differentiation by regulating transcription in the nucleus, so we examined the localization and activity of PPAR γ . Confocal microscopic analysis confirmed downregulation of PPAR γ nuclear localization and it was mainly located in the cytoplasm of G6PT $^{-/-}$ HL-60s, as compared to that in control HL-60s (Fig. 5a and S5a). Consistent with this, we found that G6PT $^{-/-}$ HL-60s showed a decrease in PPAR γ activity in the nuclear fraction (Fig. 5b).

To validate the results of the PPAR γ localization and activity test in G6PT $^{-/-}$ HL60s, we examined the expression of genes highly regulated by PPAR γ . These genes include p21 and CD38, which control cell cycle arrest and early stages of neutrophil differentiation, and CD36, ATP-binding cassette subfamily G member 1 (ABCG1), and acyl-CoA thioesterase 2 (ACOT2), which are involved in the regulation of lipid metabolism [23, 26–28]. Consequently, the expression of all these genes (p21, CD38, CD36, ABCG1, and ACOT2) were downregulated in G6PT $^{-/-}$ HL-60s (Fig. 5c and Fig. 3b). Taken together, these results indicated that G6PT deficiency inhibits the nuclear transcriptional activity of PPAR γ , thereby impairing the maturation of neutrophils.

Aberrant PU.1 and SIRT1 expression and ERK1/2 signaling in G6PT $^{-/-}$ HL-60s

Nuclear localization and transcriptional activity of PPAR γ are regulated by other transcription factors and several post-translational modifications such as deacetylation and phosphorylation [29, 30]. For example, overexpression of PU.1 is related to inhibition of genomic binding of PPAR γ and deacetylation of PPAR γ by sirtuin 1 (SIRT1) leads to repression of PPAR γ activity, thereby blocking adipogenesis [30, 31]. Also, it

was reported that phosphorylation by ERK1/2 leads to repression of PPAR γ transactivation, altering affinity for ligands and co-factors [32, 33]. In this view, we further examined PU.1 and SIRT1 protein expression and phosphorylation of ERK1/2 in *G6PT*^{-/-} HL-60s after DMSO and ATRA induction. Western blot analysis showed that protein expression of PU.1 and SIRT1 continuously increased in *G6PT*^{-/-} HL-60s compared to that in control HL-60s (Fig. 5d). In addition, we found that delayed dephosphorylation of ERK1/2 in *G6PT*^{-/-} HL-60s, indicating disturbed nuclear localization of PPAR γ (Fig. 5e). These results support our finding that impaired neutrophil differentiation results from reduced nuclear PPAR γ activity in *G6PT*^{-/-} HL-60s.

Abnormal metabolic changes in *G6PT*^{-/-} HL-60s during neutrophil differentiation

In neutrophil differentiation, a metabolic shift from glycolysis to FAO and OXPHOS/mitochondrial respiration has been reported [14, 34]. This metabolic change is fueled by the degradation of lipid droplets for FAO and mitochondrial respiration that occurs in the early stage of differentiation [14]. As the neutrophil progenitor cells become mature, the increase in mitochondrial respiration is reduced again and glycolysis increases [34]. Therefore, we investigated the impact of G6PT deficiency on the metabolic pathway by measuring the OCR and ECAR using the XF analyzer over a period of 72 h after induction. When we measured the OCR, non-mitochondrial respiration was higher in *G6PT*^{-/-} HL-60s than that in control HL-60s (Fig. 6a, b), suggesting insufficient mitochondrial electron transport or oxidative reactions in *G6PT*^{-/-} HL-60s [35]. Furthermore, it was revealed that mitochondrial respiration in *G6PT*^{-/-} HL-60s was delayed, but continuously increased without metabolic changes toward glycolysis. In line with the increase in OCR, glycolysis in both control and *G6PT*^{-/-} HL-60s decreased during neutrophil differentiation, however, control HL-60s showed re-increase of glycolysis at 72 h (Fig. 6c, d). These results suggested that the genetic loss of G6PT induces abnormal metabolic reprogramming, which underlies neutrophil maturation arrest.

Discussion

GSD-Ib is a rare inherited metabolic disorder caused by a deficiency in G6PT, which is ubiquitously expressed and plays a role in maintaining intracellular glucose homeostasis [2]. Consequently, GSD-Ib is characterized by abnormal metabolic phenotypes including hypoglycemia, hepatomegaly, nephromegaly, and abnormal metabolic profile caused by impaired gluconeogenesis and glycogenolysis [36]. GSD-Ib also exhibits neutropenia and neutrophil dysfunction, resulting in recurrent bacterial infections [2]. Previously, it has been reported that neutropenia in GSD-Ib is caused by enhanced neutrophil ER stress and apoptosis [37]. Moreover, impaired neutrophil energy homeostasis and activation of HIF-1 α /PPAR γ signaling are involved partly in neutrophil dysfunction in GSD-Ib [7]. This study observed immature neutrophils in peripheral blood in GSD-Ib patients and raised the possibility that deficiency of G6PT might induce impaired neutrophil differentiation in the BM.

In the present study, we found that immature neutrophils in the peripheral blood were highly observed in *G6pt*^{-/-} mice. Through BM examination, impaired neutrophil maturation was also identified. To investigate the molecular mechanisms governing incomplete neutrophil maturation, we knocked out the human *G6PT* gene in the promyelocyte HL-60 cell line. We found that *G6PT*^{-/-} HL-60s exhibit impaired differentiation into neutrophils (Fig. 7). This aberrant differentiation of *G6PT*^{-/-} HL-60s can be partly attributed to the decreased transcriptional activity of PPAR γ and abnormal metabolic reprogramming toward excessive mitochondrial respiration. These results indicated that G6PT plays an essential role in regulating neutrophil differentiation of myeloid progenitor cells.

The loss of G6PT activity resulted in impaired neutrophil differentiation in the HL-60s. The reasons for this result may be associated with altered metabolism of *G6PT*^{-/-} HL-60s, that is, a metabolic imbalance toward incessant mitochondrial respiration, in part supported by increased expression of the lipid metabolism regulator PPAR α and decreased lipid droplets. PPAR α primarily regulates the expression of genes related to fatty acid oxidation, and its ligand-dependent activation stimulates lipolysis and reduces fat storage [25, 38]. Consistent with the upregulation of PPAR α , there was a significant decrease in the number of lipid droplets in *G6PT*^{-/-} HL-60s. This altered metabolism may inhibit neutrophil maturation of *G6PT*^{-/-} HL-60s, since a metabolic switch from OXPHOS to glycolysis, followed by an initial increase in OXPHOS fueled by FAO, is known to occur during neutrophil differentiation [14, 34]. This excessive energy production may cause ATP depletion, thereby leading to increased expression of cleaved PARP.

Another possible explanation for aberrant neutrophil differentiation is reduced nuclear transcriptional regulation of PPAR γ in *G6PT*^{-/-} HL-60s (Fig. 5). In contrast to the function of PPAR α , PPAR γ contributes to energy storage and lipid synthesis and functions as a master regulator of adipocyte differentiation [39]. PPAR γ is mainly expressed in white adipose tissue as well as in the liver, intestine, and immune cells [40, 41]. Therefore, the differentiation induction role of PPAR γ in other cells has been investigated. In neutrophil differentiation studies, it has been reported that PPAR γ is critical for ATRA-induced neutrophil differentiation in HL-60s, regulating cell cycle arrest and receptor signaling [23]. In this study, we found decreased nuclear localization of PPAR γ in *G6PT*^{-/-} HL-60s after DMSO and ATRA induction. This was further supported by the fact that there was a reduction in the nuclear PPAR γ transcriptional activity in *G6PT*^{-/-} HL-60s and, in turn, a decrease in the mRNA expression of p21, CD36, ABCG1, and ACOT2. In addition, it leads to metabolic imbalance toward continuous increase of mitochondrial respiration in *G6PT*^{-/-} HL-60s without changes into glycolysis as that in control HL-60s.

The exact mechanism by which G6PT deficiency decreases the transcriptional activity of PPAR γ needs to be investigated, but one possible explanation is that increased expression of SIRT1 and PU.1 may repress PPAR γ transcriptional activity [30, 31]. Furthermore, upregulated phosphorylation of ERK1/2 can alter the affinity for PPAR γ ligands and co-factors, thus repressing the nuclear localization of PPAR γ in *G6PT*^{-/-} HL-60s. However, there is still a need to carry out further study in this regard.

Abbreviations

1,5-AG6P, 1,5-anhydroglucitol-6-phosphate

AAV8, adeno-associated virus serotype 8

BM, bone marrow

CEBP, CCAT/enhancer-binding protein

ECAR, extracellular acidification rate

ER, endoplasmic reticulum

ERK1/2, extracellular signal-regulated kinase 1/2

FAO, fatty acid oxidation

G-CSF, granulocyte-colony stimulating factor

G-CSFR, granulocyte-colony stimulating factor receptor

G6P, glucose-6-phosphate

G6Pase, glucose-6-phosphatase

G6PT, glucose-6-phosphate transporter

GFI1, growth factor independent 1 transcriptional repressor

GSD-Ib, glycogen storage disease type Ib

HIF-1 α , hypoxia-inducible factor-1- α

OCR, oxygen consumption rate

OXPHOS, oxidative phosphorylation

PARP, poly (ADP-ribose) polymerase

PPAR α , peroxisome proliferator-activated receptor- α

PPAR γ , peroxisome proliferator-activated receptor- γ

SIRT1, NAD-dependent protein deacetylase sirtuin 1

Declarations

Acknowledgments

We thank Dr. Janice Chou at the National Institute of Child Health and Human Development for providing *G6pt^{-/-}* mice and the AAV-gene therapy vector containing human G6PT for this study. We also thank the Global Center for GSD for grant support along with the following GSD-lb philanthropy funds managed by the University of Connecticut Foundation: The Catherine McMillan Fund, The Jamie Konieczka Fund, The Jonah Pournazarian Fund, The Nina Contreras D'Agosto Fund, and The Sophie LaFreniere GSD-lb Fund.

Funding

This work was carried out with the support of the Korea Medical Device Development Fund grant funded by the Korean government (Ministry of Science and ICT, Ministry of Trade, Industry and Energy, Ministry of Health & Welfare, and Ministry of Food and Drug Safety; 202012E04). Additional support was provided by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2021R1I1A3056109).

Competing interests

The authors have no relevant financial or non-financial interests to disclose

Author contributions

S.W.S. designed and performed the research, analyzed data, and wrote the paper. Y.Y.J., P.T.S., and P.B.C. analyzed data and wrote the paper. H.S.J. and Y.M.L. designed the research, analyzed data, and wrote the paper.

Data availability

Data available on request from the authors.

Conflict of interest disclosure

The authors declare no conflict of interest.

Ethics approval

All animal studies were conducted under an animal protocol approved by the Institutional Animal Care and Use Committee of the University of Connecticut School of Medicine.

Consent to participate

Not applicable

Consent to publish

Not applicable

References

1. Chou JY, Jun HS, Mansfield BC (2010) Glycogen storage disease type I and G6Pase-beta deficiency: etiology and therapy. *Nat Rev Endocrinol* 6:676–688. <https://doi.org/10.1038/nrendo.2010.189>
2. Chou JY, Jun HS, Mansfield BC (2010) Neutropenia in type Ib glycogen storage disease. *Curr Opin Hematol* 17:36–42. <https://doi.org/10.1097/MOH.0b013e328331df85>
3. Hiraiwa H, Pan CJ, Lin B, Moses SW, Chou JY (1999) Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b. *J Biol Chem* 274:5532–5536. <https://doi.org/10.1074/jbc.274.9.5532>
4. Chou JY, Matern D, Mansfield BC, Chen YT (2002) Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. *Curr Mol Med* 2:121–143. <https://doi.org/10.2174/1566524024605798>
5. Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, Ullrich K, Smit GP (2000) Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. *J Pediatr* 137:187–191. <https://doi.org/10.1067/mpd.2000.105232>
6. Sim SW, Weinstein DA, Lee YM, Jun HS (2020) Glycogen storage disease type Ib: role of glucose-6-phosphate transporter in cell metabolism and function. *FEBS Lett* 594:3–18. <https://doi.org/10.1002/1873-3468.13666>
7. Jun HS, Weinstein DA, Lee YM, Mansfield BC, Chou JY (2014) Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib. *Blood* 123:2843–2853. <https://doi.org/10.1182/blood-2013-05-502435>
8. Calderwood S, Kilpatrick L, Douglas SD, Freedman M, Smith-Whitley K, Rolland M, Kurtzberg J (2001) Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. *Blood* 97:376–382. <https://doi.org/10.1182/blood.v97.2.376>
9. Kim GY, Lee YM, Kwon JH, Jun HS, Chou J (2017) Glycogen storage disease type Ib neutrophils exhibit impaired cell adhesion and migration. *Biochem Biophys Res Commun* 482:569–574. <https://doi.org/10.1016/j.bbrc.2016.11.075>
10. Li AM, Thyagu S, Maze D, Schreiber R, Sirrs S, Stockler-Ipsiroglu S, Sutherland H, Vercauteren S, Schultz KR (2018) Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length. *Pediatr Hematol Oncol* 35:45–51. <https://doi.org/10.1080/08880018.2018.1440675>
11. Veiga-da-Cunha M, Chevalier N, Stephenne X, Defour JP, Paczia N, Ferster A, Achouri Y, Dewulf JP, Linster CL, Bommer GT, Van Schaftingen E (2019) Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. *Proc Natl Acad Sci U S A* 116:1241–1250. <https://doi.org/10.1073/pnas.1816143116>

12. Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A, Oussoren E, Mayr JA, van Spronsen FJ, Lagler FB, Gaughan S, Van Schaftingen E, Veiga-da-Cunha M (2020) Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. *Blood* 136:1033–1043. <https://doi.org/10.1182/blood.2019004465>
13. Bainton DF, Ulliyot JL, Farquhar MG (1971) The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. *J Exp Med* 134:907–934
14. Riffelmacher T, Clarke A, Richter FC, Stranks A, Pandey S, Danielli S, Hublitz P, Yu Z, Johnson E, Schwerd T, McCullagh J, Uhlig H, Jacobsen SEW, Simon AK (2017) Autophagy-Dependent Generation of Free Fatty Acids Is Critical for Normal Neutrophil Differentiation. *Immunity* 47:466–480e465. <https://doi.org/10.1016/j.immuni.2017.08.005>
15. Six E, Lagresle-Peyrou C, Susini S, De Chappedelaine C, Sigrist N, Sadek H, Chouteau M, Cagnard N, Fontenay M, Hermine O, Chomienne C, Reynier P, Fischer A, Andre-Schmutz I, Gueguen N, Cavazzana M (2015) AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages. *Cell Death Dis* 6:e1856. <https://doi.org/10.1038/cddis.2015.211>
16. Rozman S, Yousefi S, Oberson K, Kaufmann T, Benarafa C, Simon HU (2015) The generation of neutrophils in the bone marrow is controlled by autophagy. *Cell Death Differ* 22:445–456. <https://doi.org/10.1038/cdd.2014.169>
17. Kwon JH, Lee YM, Cho JH, Kim GY, Anduaga J, Starost MF, Mansfield BC, Chou JY (2017) Liver-directed gene therapy for murine glycogen storage disease type Ib. *Hum Mol Genet* 26:4395–4405. <https://doi.org/10.1093/hmg/ddx325>
18. Sim SW, Park TS, Kim SJ, Park BC, Weinstein DA, Lee YM, Jun HS (2018) Aberrant proliferation and differentiation of glycogen storage disease type Ib mesenchymal stem cells. *FEBS Lett* 592:162–171. <https://doi.org/10.1002/1873-3468.12939>
19. Messina-Graham S, Broxmeyer H (2016) SDF-1/CXCL12 modulates mitochondrial respiration of immature blood cells in a bi-phasic manner. *Blood Cells Mol Dis* 58:13–18. <https://doi.org/10.1016/j.bcmd.2016.01.008>
20. Chen LY, Shieh JJ, Lin B, Pan CJ, Gao JL, Murphy PM, Roe TF, Moses S, Ward JM, Lee EJ, Westphal H, Mansfield BC, Chou JY (2003) Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. *Hum Mol Genet* 12:2547–2558. <https://doi.org/10.1093/hmg/ddg263>
21. Yiu WH, Pan CJ, Mead PA, Starost MF, Mansfield BC, Chou JY (2009) Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice. *J Hepatol* 51:909–917. <https://doi.org/10.1016/j.jhep.2008.11.026>
22. McDermott DH, De Ravin SS, Jun HS, Liu Q, Priel DA, Noel P, Takemoto CM, Ojode T, Paul SM, Dunsmore KP, Hilligoss D, Marquesen M, Ulrick J, Kuhns DB, Chou JY, Malech HL, Murphy PM (2010) Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4

- expression and myelokathexis. *Blood* 116:2793–2802. <https://doi.org/10.1182/blood-2010-01-265942>
23. Tasseff R, Jensen HA, Congleton J, Dai D, Rogers KV, Sagar A, Bunaciu RP, Yen A, Varner JD (2017) An Effective Model of the Retinoic Acid Induced HL-60 Differentiation Program. *Sci Rep* 7:14327. <https://doi.org/10.1038/s41598-017-14523-5>
 24. Kumar S, Dikshit M (2019) Metabolic Insight of Neutrophils in Health and Disease. *Front Immunol* 10:2099. <https://doi.org/10.3389/fimmu.2019.02099>
 25. Grygiel-Gorniak B (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review. *Nutr J* 13:17. <https://doi.org/10.1186/1475-2891-13-17>
 26. Christofides A, Konstantinidou E, Jani C, Boussiotis VA (2021) The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. *Metabolism* 114:154338. <https://doi.org/10.1016/j.metabol.2020.154338>
 27. Schmitz G, Langmann T, Heimerl S (2001) Role of ABCG1 and other ABCG family members in lipid metabolism. *J Lipid Res* 42:1513–1520
 28. Hunt MC, Alexson SE (2002) The role Acyl-CoA thioesterases play in mediating intracellular lipid metabolism. *Prog Lipid Res* 41:99–130. [https://doi.org/10.1016/s0163-7827\(01\)00017-0](https://doi.org/10.1016/s0163-7827(01)00017-0)
 29. Choi SS, Park J, Choi JH (2014) Revisiting PPARgamma as a target for the treatment of metabolic disorders. *BMB Rep* 47:599–608. <https://doi.org/10.5483/bmbrep.2014.47.11.174>
 30. Dispirito JR, Fang B, Wang F, Lazar MA (2013) Pruning of the adipocyte peroxisome proliferator-activated receptor gamma cistrome by hematopoietic master regulator PU.1. *Mol Cell Biol* 33:3354–3364. <https://doi.org/10.1128/MCB.00599-13>
 31. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, Guarente L (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. *Nature* 429:771–776. <https://doi.org/10.1038/nature02583>
 32. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK (1997) Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. *J Biol Chem* 272:5128–5132. <https://doi.org/10.1074/jbc.272.8.5128>
 33. Camp HS, Tafuri SR (1997) Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. *J Biol Chem* 272:10811–10816. <https://doi.org/10.1074/jbc.272.16.10811>
 34. Albanesi J, Noguera NI, Banella C, Colangelo T, De Marinis E, Leone S, Palumbo O, Voso MT, Ascenzi P, Nervi C, Bianchi F, di Masi A (2020) Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. *Cells* 9. <https://doi.org/10.3390/cells9112423>
 35. Herst PM, Tan AS, Scarlett DJ, Berridge MV (2004) Cell surface oxygen consumption by mitochondrial gene knockout cells. *Biochim Biophys Acta* 1656:79–87. <https://doi.org/10.1016/j.bbabi.2004.01.008>

36. Chou JY (2001) The molecular basis of type 1 glycogen storage diseases. *Curr Mol Med* 1:25–44
37. Kim SY, Jun HS, Mead PA, Mansfield BC, Chou JY (2008) Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib. *Blood* 111:5704–5711.
<https://doi.org/10.1182/blood-2007-12-129114>
38. Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, Piomelli D (2004) Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). *J Biol Chem* 279:27849–27854. <https://doi.org/10.1074/jbc.M404087200>
39. Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S (2014) PPARgamma and the global map of adipogenesis and beyond. *Trends Endocrinol Metab* 25:293–302.
<https://doi.org/10.1016/j.tem.2014.04.001>
40. Cariou B, Charbonnel B, Staels B (2012) Thiazolidinediones and PPARgamma agonists: time for a reassessment. *Trends Endocrinol Metab* 23:205–215. <https://doi.org/10.1016/j.tem.2012.03.001>
41. Croasdell A, Duffney PF, Kim N, Lacy SH, Sime PJ, Phipps RP (2015) PPARgamma and the Innate Immune System Mediate the Resolution of Inflammation. *PPAR Res* 2015:549691.
<https://doi.org/10.1155/2015/549691>

Figures

Figure 1

Neutropenia and abnormal G-CSFR and CXCR4 expression in the peripheral blood of *G6pt*^{-/-} mice. **a** Representative flow cytometry data (left) and frequency of CD11b⁺Gr-1⁺ neutrophils in the blood of control (WT) and *G6pt*^{-/-} mice. **b** Representative Hema-3-stained cytopins of peripheral blood neutrophils (bar = 20 mm). **c** Representative flow cytometry analysis and mean fluorescence intensity (MFI) of granulocyte-colony stimulating factor receptor (G-CSFR) on CD11b⁺Gr-1⁺ cells. **d** Representative flow cytometry analysis and MFI of C-X-C chemokine receptor type 4 (CXCR4) on CD11b⁺Gr-1⁺ cells. Data have been represented as mean $\pm$ SEM (*n*=8 per genotype). ** *P*<0.01.

Figure 2

Accumulation of neutrophil precursor cells in the bone marrow of *G6pt*^{-/-} mice. **a** Representative flow cytometry data (left) and frequency of mature (CD11b⁺Gr-1⁺), immature neutrophil precursors (CD11b⁻Gr-1⁺), and ratio of immature (CD11b⁻Gr-1⁺/Gr-1⁺) cells in the bone marrow of control (WT) and *G6pt*^{-/-} mice. **b** Representative flow cytometry analysis and mean fluorescence intensity (MFI) of granulocyte-colony stimulating factor receptor (G-CSFR) on Gr-1⁺ cells. **c** Representative flow cytometry analysis and MFI of C-X-C chemokine receptor type 4 (CXCR4) on Gr-1⁺ cells. **d** Representative Hema-3-stained cytopins of isolated bone marrow neutrophil lineage cells (bar = 20 mm). Data have been represented as mean ± SEM (n=3 per genotype). * *P*<0.05, ** *P*<0.01.

Figure 3

Impaired neutrophil differentiation in *G6PT*^{-/-} human promyelocyte HL-60s. **a** Growth curve of control and *G6PT*^{-/-} HL-60s for the indicated times in the normal (left) and neutrophil differentiation-induced (right) conditions. **b** Frequency of CD38⁺CD71⁻ cells and mean fluorescence intensity (MFI) of CD38 expression for the indicated time after differentiation induction. **c** Frequency of CD11b⁺CD71⁻ cells at the indicated time. **d** Representative Hema-3-stained cytopins of dimethyl sulfoxide (DMSO) and all-trans retinoic acid (ATRA)-induced control and *G6PT*^{-/-} HL-60s (bar = 10 mm). **e** Frequency of annexin V-positive apoptotic cells at the indicated time. Data have been represented as mean ± SEM (n=3). * *P*<0.05, ** *P*<0.01.

Figure 4

Aberrant regulation of lipid metabolism by PPAR γ and PPAR α in *G6PT*^{-/-} HL-60s. **a** Representative images of BODIPY-stained lipid droplets of control and *G6PT*^{-/-} HL-60s (bar = 10 mm) after dimethyl sulfoxide (DMSO) and all-trans retinoic acid (ATRA) induction (left) and quantification of lipid droplets (right). **b** mRNA levels of peroxisome proliferator-activated receptor- γ (PPAR γ) and peroxisome proliferator-activated receptor- α (PPAR α). **c** Western blot analysis and quantification of PPAR γ and PPAR α . Data have been represented as mean $\pm$ SEM (n=3). * $P < 0.05$, ** $P < 0.01$.

Figure 5

Decreased nuclear localization and transcriptional activity of PPAR γ in *G6PT*^{-/-} HL-60s. **a** Confocal analysis of peroxisome proliferator-activated receptor- γ (PPAR γ , red fluorescence) and DAPI staining (blue fluorescence) at original magnification of 400 $\times$ (bar = 10 μ m). **b** Relative fold change of nuclear PPAR γ activity. **c** mRNA levels of p21, CD36, ATP-binding cassette subfamily G member 1 (ABCG1), and acyl-CoA thioesterase 2 (ACOT2). **d** Protein levels of PU.1 and NAD-dependent protein deacetylase sirtuin 1 (SIRT1). **e** Western blot analyses of phosphorylated and total extracellular signal-regulated kinase 1/2 (ERK1/2). The ratio of the phosphorylated form to the total form is shown on the right. Data have been represented as mean $\pm$ SEM (n=3). * $P < 0.05$, ** $P < 0.01$.

Figure 6

Measurement of the mitochondrial oxygen consumption rate and extracellular acidification rate of control and *G6PT*^{-/-} HL-60s during neutrophil differentiation. **a** Kinetic profile of oxygen consumption rate (OCR) assay of control and *G6PT*^{-/-} HL-60s. OCR was measured in real-time in response to three compounds; oligomycin (OM), FCCP, and rotenone/antimycin A (R/AA). **b** Individual plots for non-mitochondrial respiration, basal respiration, maximal respiratory capacity, and ATP production. **c** Determination of extracellular acidification rate (ECAR). **d** Individual plots for glycolysis and glycolytic reserve. Data have been represented as mean $\pm$ SEM (n=3). * $P<0.05$, ** $P<0.01$.

G6PT-deficient HL-60s

Figure 7

Proposed mechanisms underlying maturation arrest caused by glucose-6-phosphate transporter (G6PT) deficiency during neutrophil development. G6PT deficiency causes impaired neutrophil differentiation, as compared to that seen in control HL-60s. This phenotype can be explained by two proposed mechanisms. Metabolic reprogramming in *G6PT*^{-/-} HL-60s causes a shift toward excessive mitochondrial oxidative phosphorylation, which is associated with upregulation of peroxisome proliferator-activated receptor- α and reduced accumulation of lipid droplets. In addition, decreased nuclear localization and transcriptional activity of peroxisome proliferator-activated receptor- γ (PPAR γ) impair cell cycle arrest and PPAR γ -induced transcriptional regulations in *G6PT*^{-/-} HL-60s during neutrophil differentiation.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SWSimssupplementarymaterialCMLS2201172040.pdf](#)